Background colour

PREVIEW

Image

AssetID: 41013768

Headline: Russian Vaccine: First Interim Data Analysis Of Covid-19 Sputnik V Vaccine Phase III Clinical Trials Demonstrated 92% Efficacy

Caption: Announced Weds (11 Nov), the Sputnik V vaccine efficacy amounted to 92% (calculation based on the 20 confirmed COVID-19 cases split between vaccinated individuals and those who received the placebo). Currently 40,000 volunteers are taking part in double-blind, randomized, placebo-controlled Phase III of Sputnik V clinical trials, out of which over 20,000 have been vaccinated with the first dose of the vaccine and more than 16,000 with both the first and second doses of the vaccine. The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), announce that the Sputnik V vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of August under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy.

Keywords: interesting,news,health,virus,disease,flu,pandemic,outbreak,China,Chinese,science,tech,technology,covid,covid-19,covid19,SARS-CoV-2,sars,coronavirus,infection,infected,lockdown,lock down,research,vaccine,russia,Russian

PersonInImage: